GALLANT-1: Galectin-3 (Gal-3) inhibitor, GB1211, plus atezolizumab (atz) in patients (pts) with non-small cell lung cancer (NSCLC) - a dose finding study followed by a randomised, double-blind, placebo-controlled trial

被引：1

作者：

Ghiringhelli, F. ^{[1
]}

Barre, P. ^{[2
]}

Pichon, E. ^{[3
]}

Aix, S. Ponce ^{[4
]}

Vidal, O. J. Juan ^{[5
]}

Costa, E. Carcereny ^{[6
]}

Sethi, T. ^{[7
]}

Lindmark, B. ^{[8
]}

MacKinnon, A. ^{[7
]}

Aslanis, V. ^{[9
]}

Phung, D. H. ^{[10
]}

Jensen, P. ^{[11
]}

Rajiwate, Z. ^{[12
]}

Ross, G. ^{[8
]}

Basse, L. ^{[8
]}

机构：

[1] Univ Burgundy, Genet & Immuno therapy Med Inst, Ctr Georges Francois Leclerc, Dijon, France

[2] Montpellier Reg Univ Hosp, Dept Thorac Oncol, Montpellier, France

[3] CHRU Bretonneau, Serv Pneumol, Tours, France

[4] Hosp Univ 12 Octubre, Dept Med Oncol, Madrid, Spain

[5] La Fe Univ Hosp, Dept Med Oncol, Valencia, Spain

[6] Germans Trias & Pujol Hosp, Catalan Inst Oncol Badalona, Dept Med Oncol, Barcelona, Spain

[7] Galecto Biotech AB, Pre Clin Res & Dev, Copenhagen, Denmark

[8] Galecto Biotech AB, Clin Res & Dev, Copenhagen, Denmark

[9] Galecto Biotech AB, Pharmacokinet, Copenhagen, Denmark

[10] Galecto Biotech AB, Biostat, Copenhagen, Denmark

[11] Galecto Biotech AB, Project Management, Copenhagen, Denmark

[12] Galecto Biotech AB, Clin Operat, Copenhagen, Denmark

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期

关键词：

D O I：

10.1016/j.annonc.2022.07.1315

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1192TiP

引用

页码：S1093 / S1094

页数：2

共 50 条

[31] Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Wang, Jie
Zhou, Caicun
Yao, Wenxiu
Wang, Qiming
Min, Xuhong
Chen, Gongyan
Xu, Xingxiang
Li, Xingya
Xu, Fei
Fang, Yong
Yang, Runxiang
Yu, Guohua
Gong, Youling
Zhao, Jun
Fan, Yun
Liu, Quan
Cao, Lejie
Yao, Yu
Liu, Yunpeng
Li, Xiaoling
Wu, Jingxun
He, Zhiyong
Lu, Kaihua
Jiang, Liyan
Hu, Chengping
Zhao, Wenhua
Zhang, Ben
Shi, Wei
Zhang, Xiaojing
Cheng, Ying
LANCET ONCOLOGY, 2022, 23 (06): : 739 - 747
[32] Double-Blind, Placebo-Controlled, Randomized Phase 2 Study of the Proapoptotic Agent AT-101 Plus Docetaxel, in Second-Line Non-small Cell Lung Cancer
Ready, Neal
Karaseva, Nina A.
Orlov, Sergey V.
Luft, Alexander V.
Popovych, Olexandr
Holmlund, Jon T.
Wood, Brian A.
Leopold, Lance
JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (04) : 781 - 785
[33] The effect of multivitamin and mineral complex on natural killer cell activity in surgically resected non-small cell lung cancer patients: A randomized, double-blind placebo-controlled study
Kim, Jiwon
Choi, Chang-Min
Kim, Hyeong Ryul
Lee, Geun Dong
Gil, Minchan
Lee, Hyeja
Kim, Hye Rim
Ji, Wonjun
Lee, Seung Hyeun
RESPIROLOGY, 2023, 28 : 322 - 322
[34] A multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical effects of pacilitaxel-carboplatin (TC) alone or with endostatin for advanced non-small cell lung cancer (NSCLC)
Han, B.
Xiu, Q.
Luo, Y.
Bai, C.
Guo, S.
Liu, W.
Zhuang, Z.
Zhang, Y.
Zhou, J.
Jin, X.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[35] CCTG BR.31: A global, double-blind placebo-controlled, randomized phase III study of adjuvant durvalumab in completely resected non-small cell lung cancer (NSCLC)
Goss, G.
Darling, G. E.
Westeel, V.
Nakagawa, K.
Massuti Sureda, B.
Perrone, F.
McLachlan, S-A.
Kang, J. H.
Wu, Y-L.
Dingemans, A-M. C.
Dziadziuszko, R.
Okada, M.
Greillier, L.
Audigier-Valette, C.
Sugawara, S.
Nadal, E.
Catino, A.
Stockler, M. R.
Ding, K.
O'Callaghan, C.
ANNALS OF ONCOLOGY, 2024, 35 : 1238 - 1238
[36] Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study
Ciuleanu, Tudor
Brodowicz, Thomas
Zielinski, Christoph
Kim, Joo Hang
Krzakowski, Maciej
Laack, Eckart
Wu, Yi-Long
Bover, Isabel
Begbie, Stephen
Tzekova, Valentina
Cucevic, Branka
Pereira, Jose Rodrigues
Yang, Sung Hyun
Madhavan, Jayaprakash
Sugarman, Katherine P.
Peterson, Patrick
John, William J.
Krejcy, Kurt
Belani, Chandra P.
LANCET, 2009, 374 (9699): : 1432 - 1440
[37] The efficacy and safety of TQ-B2450 alone/with anlotinib in previously treated advanced non-small cell lung cancer (NSCLC): A multicenter, randomized, double-blind, placebo-controlled clinical trial
Han, B.
Li, K.
Wang, Q.
Cheng, Y.
Yang, L.
Li, Y.
ANNALS OF ONCOLOGY, 2021, 32 : S1429 - S1429
[38] Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC)
Tran, Hai T.
Zinner, Ralph G.
Blumenschein, George R., Jr.
Oh, Yun W.
Papadimitrakopoulou, Vassiliki A.
Kim, Edward S.
Lu, Charles
Malik, Mubashira
Lum, Bert L.
Herbst, Roy S.
INVESTIGATIONAL NEW DRUGS, 2011, 29 (03) : 499 - 505
[39] Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC)
Hai T. Tran
Ralph G. Zinner
George R. Blumenschein
Yun W. Oh
Vassiliki A. Papadimitrakopoulou
Edward S. Kim
Charles Lu
Mubashira Malik
Bert L. Lum
Roy S. Herbst
Investigational New Drugs, 2011, 29 : 499 - 505
[40] Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
Garassino, Marina C.
Gadgeel, Shirish
Esteban, Emilio
Felip, Enriqueta
Speranza, Giovanna
Domine, Manuel
Hochmair, Maximilian
Powell, Steve
Cheng, Susanna Yee-Shan
Bischoff, Helge G.
Peled, Nir
Reck, Martin
Hui, Rina
Garon, Edward B.
Boyer, Michael
Wei, Ziwen
Burke, Thomas
Pietanza, M. Catherine
Rodriguez-Abreu, Delvys
LANCET ONCOLOGY, 2020, 21 (03): : 387 - 397

← 1 2 3 4 5 →